Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of light-activated small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which research, develops, manufactures and distributes cool laser therapy (CLT) systems to healthcare practitioners, predominantly for the healing of pain.


TSXV:TLT - Post by User

Theralase Technologies Inc.
Bullboard Posts
User Avatar Image
(510)
•••
Comment by 2b7f6fabon Jun 25, 2017 9:28pm
135 Views
Post# 26403425

RE:RE:RE:RE:The makers of Photofrin

RE:RE:RE:RE:The makers of Photofrindear bionic basement dweller.

how about you go fus?


bionicjoe wrote:
bencro wrote: GotTime ... Thanks for taking the time to debunk this amateur clown Bionicjoke.

He deliberately manipulates in every of his posts.  And shows his incompetency on all topics.

_________________

Concordia's stock issues are well-known and well documented.  They also have absolutely nothing to do with the drug Photofrin. You clearly try to cause panic with your misleading posts and your actions seem more and more desperate.

Concordia story for any who don't know - 

They had astronomical growth through acquisition and took on billions of dollars of debt.  The drastic SP fall was what ensued when the levels of their debt were revealed.  Absolutely nothing to do with Photofrin.

Strongly recommend ignoring this user's posts and intentional misdirection.

 


To be fair bencro you should post my response to Got Time.

You do strive to be fair don't you?

A lot of reasons accounting for Concordia's downfall not the least of which is the failure of their PDT Photofrin to drive up sales after they acquired the rights from Pinnacle Biologics. PDT still remains a scientific curiosity until proven otherwise. One SH poster was excited about the possibility of TLT obtaining Orphan status for their medical procedure. Maybe he should have a look at Concordia's money losing Orphan Drug Division of which PDT is their star attraction.

It doesn't matter which way you spin it the bottom line remains that the market isn't willing to let the sp get ahead of itself based only on pre-clinical data. If you don't recognize that fact then either you are a bad biotech investor or deluding yourself.

A lot of shareholders are expecting a NR on efficacy from the cystoscopy results before the end of next week. Once again this SH board marches to its own tune. I don't recall RW ever saying he would do a PR following the cystoscopy scans but people will believe what they want to believe. It's likely Dr. Lilge and Dr. Kulkarni will just touch on the outcome of the scans during their AGM presentations without drawing any conclusions on efficacy. How would the market take that is anybody's guess?



Bullboard Posts
Dealroom for high-potential pre-IPO opportunities